CLMT Stock Analysis: Calumet Specialty Products | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 3.022m USD | 12M Return: 72.1% | US1314281049 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 71.1M
Qual. Beats: 1
Rev. Trend: 40.7%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Calumet Specialty Products Partners (NASDAQ: CLMT) is a U.S.-based manufacturer and marketer of specialty branded products and renewable fuels, operating through three segments: Specialty Products and Solutions (solvents, waxes, lubricating oils, white oils, petrolatums, gels, and esters), Performance Brands (high-performance products sold under the Royal Purple, Bel-Ray, and TruFuel labels), and Montana/Renewables, which processes renewable feedstocks into renewable diesel, aviation fuel, and renewable naphtha, and also refines Canadian crude into gasoline, diesel, jet fuel, and specialty asphalt. The company sells to wholesale distributors and retail chains across North America and internationally, and was founded in 1919 with headquarters in Indianapolis, Indiana. Classified within the Energy sectors Oil & Gas Refining & Marketing sub-industry, Calumets business model blends higher-margin specialty chemical and lubricant offerings with commodity-scale renewable and conventional fuel production, a mix that diversifies revenue streams but ties overall results to both specialty product demand and refining margins.
- Montana renewables segment expands renewable diesel capacity
- Specialty solvents pricing drives segment margin expansion
- Performance Brands grows on Royal Purple and Bel-Ray demand
| Net Income: -193.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 11.62 > 1.0 |
| NWC/Revenue: 1.42% < 20% (prev 2.56%; Δ -1.14% < -1%) |
| CFO/TA 0.11 > 3% & CFO 341.1m > Net Income -193.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.0m) vs 12m ago 1.51% < -2% |
| Gross Margin: 9.06% > 18% (prev 8.21%; Δ 0.86% > 0.5%) |
| Asset Turnover: 181.4% > 50% (prev 148.1%; Δ 33.37% > 0%) |
| Interest Coverage Ratio: -0.96 > 6 (EBIT TTM -196.2m / Interest Expense TTM 204.7m) |
| A: 0.02 (Total Current Assets 1.24b - Total Current Liabilities 1.17b) / Total Assets 2.99b |
| B: -0.58 (Retained Earnings -1.73b / Total Assets 2.99b) |
| C: -0.07 (EBIT TTM -196.2m / Avg Total Assets 2.86b) |
| D: -0.24 (Book Value of Equity -870.7m / Total Liabilities 3.60b) |
| Altman-Z'' = -2.44 = D |
| DSRI: 1.30 (Receivables 466.0m/278.7m, Revenue 5.20b/4.05b) |
| GMI: 0.91 (GM 8.21% / 9.06%) |
| AQI: 0.85 (AQ_t 0.15 / AQ_t-1 0.18) |
| SGI: 1.28 (Revenue 5.20b / 4.05b) |
| TATA: -0.18 (NI -193.8m - CFO 341.1m) / TA 2.99b) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of November 17, 2026, the stock is trading at USD 31.96 with a total of 1,695,138 shares traded. Over the past week, the price has changed by -11.37%, over one month by -44.66%, over three months by -33.90% and over the past year by +72.11%.
Current recommended Stop Loss: 28.30 (which is 11.5% or 1.3 ATR below the current price).
Calumet Specialty Products has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold CLMT.
- StrongBuy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 55.8 | 74.6% |
P/E Forward = 16.6389
P/S = 0.5815
P/B = 19.3228
P/EG = 0.6537
Revenue TTM = 5.20b USD
EBIT TTM = -196.2m USD
EBITDA TTM = -39.0m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 2.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 225.6m
Net Debt = 2.17b USD (calculated: Debt 2.40b - CCE 225.2m)
Enterprise Value = 5.19b USD (3.02b + Debt 2.40b - CCE 225.2m)
Interest Coverage Ratio = -0.96 (Ebit TTM -196.2m / Interest Expense TTM 204.7m)
EV/FCF = 19.59x (Enterprise Value 5.19b / FCF TTM 265.1m)
FCF Yield = 5.10% (FCF TTM 265.1m / Enterprise Value 5.19b)
FCF Margin = 5.10% (FCF TTM 265.1m / Revenue TTM 5.20b)
Net Margin = -3.73% (Net Income TTM -193.8m / Revenue TTM 5.20b)
Gross Margin = 9.06% ((Revenue TTM 5.20b - Cost of Revenue TTM 4.73b) / Revenue TTM)
Gross Margin QoQ = 32.28% (prev 1.27%)
Tobins Q-Ratio = 1.73 (Enterprise Value 5.19b / Total Assets 2.99b)
Interest Expense / Debt = 8.54% (Interest Expense 204.7m / Debt 2.40b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -155.0m (EBIT -196.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.06 (Total Current Assets 1.24b / Total Current Liabilities 1.17b)
Debt / Equity = -2.75 (negative equity) (Debt 2.40b / totalStockholderEquity, last quarter -870.7m)
Debt / EBITDA = -55.70 (negative EBITDA) (Net Debt 2.17b / EBITDA -39.0m)
Debt / FCF = 8.19 (Net Debt 2.17b / FCF TTM 265.1m)
Total Stockholder Equity = -945.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.77% (Net Income -193.8m / Total Assets 2.99b)
RoE = 20.49% (negative equity) (Net Income TTM -193.8m / Total Stockholder Equity -945.9m)
RoCE = -16.26% (EBIT -196.2m / Capital Employed (Equity -945.9m + L.T.Debt 2.15b))
RoIC = -9.56% (negative operating profit) (NOPAT -155.0m / Invested Capital 1.62b)
WACC = 8.09% (E(3.02b)/V(5.42b) * Re(9.16%) + D(2.40b)/V(5.42b) * Rd(8.54%) * (1-Tc(0.21)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.77 | Cagr: 4.02%
[DCF] Terminal Value 75.44% ; FCFF base≈265.1m ; Y1≈266.2m ; Y5≈282.0m
[DCF] Fair Price = 25.13 (EV 4.39b - Net Debt 2.17b = Equity 2.21b / Shares 88.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 40.67 | Revenue CAGR: 3.13% | SUE: 3.24 | # QB: 3
EPS current Quarter (2027-03-31): EPS=1.16 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.68 | Chg30d=+323.76% | Revisions=+25% | GrowthEPS=+242.9% | GrowthRev=+27.6%
EPS next Year (2027-12-31): EPS=4.01 | Chg30d=+536.51% | Revisions=+25% | GrowthEPS=+493.3% | GrowthRev=-6.1%
[Analyst] Revisions Ratio: +50% (up=3, down=0)